Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.55 |
| ▸ | HTR2A | P28223 | 6/20 | 0.49 |
| ▸ | HTR7 | P34969 | 6/20 | 0.49 |
| ▸ | DRD2 | P14416 | 5/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.43 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3239367 | 0.89 | HRH3 (0.60) | HRH3KDM4EBRD4ALDH1A1POLB | |
| SCHEMBL3240674 | 0.88 | HRH3 (0.60) | HRH3HTR2AHTR7DRD2KCNH2 | |
| SCHEMBL3249663 | 0.88 | KDM4E (0.57) | HRH3KCNH2KDM4EBRD4ALDH1A1 | |
| SCHEMBL3247741 | 0.86 | HRH3 (0.57) | HRH3KDM4EBRD4ALDH1A1POLB | |
| SCHEMBL3239237 | 0.86 | HRH3 (0.58) | HRH3HTR2AHTR7DRD2KCNH2 | |
| SCHEMBL3242821 | 0.85 | HRH3 (0.59) | HRH3HTR2AHTR7DRD2KCNH2 | |
| SCHEMBL27746330 | 0.85 | HRH3 (0.56) | HRH3KDM4EBRD4ALDH1A1POLB | |
| SCHEMBL3240701 | 0.84 | HRH3 (0.57) | HRH3KDM4EBRD4ALDH1A1POLB | |
| SCHEMBL3239210 | 0.84 | HRH3 (0.58) | HRH3HTR2AHTR7DRD2KCNH2 | |
| SCHEMBL3245572 | 0.84 | HRH3 (0.57) | HRH3KDM4EBRD4ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069331-B1 | 1H-INDOL-6-YL-PIPERAZIN-1-YL-METHANONE-DERIVATIVES FOR USE AS H3 RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2010-05-05 | — | — | EP | disclosed |
| EP-2069331-A1 | 1H-INDOL-6-YL-PIPERAZIN-1-YL-METHANONE-DERIVATIVES FOR USE AS H3 RECEPTOR MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-06-17 | — | — | EP | disclosed |
| US-7514433-B2 | 1H-indole-6-yl-piperazin-1-yl-methanone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20080032976-A1 | 1H-indole-6-yl-piperazin-1-yl-methanone derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2008-02-07 | — | — | US | disclosed |
| WO-2008015125-A1 | 1H-INDOL-6-YL-PIPERAZIN-1-YL-METHANONE-DERIVATIVES FOR USE AS H3 RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080032976-A1 | 1H-indole-6-yl-piperazin-1-yl-methanone derivatives | HTR6, HTR1A, HRH4 | HRH3 5/4885HTR2A 34/4885HTR7 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.